Abstract
Tryptanthrin, an indole quinazoline alkaloid with multiple medical activities, has been recently under preclinical development as an anti-tuberculosis and anti-tumor drug. The aims of this study are to characterize the intestinal transport of tryptanthrin in Caco-2 cells, to determine whether P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2) are involved in this issue, and to evaluate the potential influence of tryptanthrin on the function of P-gp and MRP2. Transport assays of tryptanthrin were performed in Caco-2 monolayers with or without the supplement of P-gp and MRP2 inhibitors. Results showed that tryptanthrin was well absorbed across the Caco-2 monolayers, and its transepithelial transports were dominated by passive diffusion. Tryptanthrin was not a substrate, but a potential inhibitor of P-gp and MRP2.
Introduction
Tryptanthrin is a natural indole quinazoline alkaloid (Figure 1) that has shown significant promise as a therapeutic agent for multi-drug resistant tuberculosis and various cancers. However, the clinical success of any drug candidate depends heavily on its pharmacokinetic profile, particularly its ability to be absorbed in the gut.
A major obstacle to intestinal absorption is the presence of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp) and Multidrug Resistance-associated Protein 2 (MRP2). These proteins function as efflux pumps, ejecting foreign molecules from intestinal cells back into the gut lumen. This study investigates whether tryptanthrin is a "victim" (substrate) of these pumps or if it acts as an inhibitor, which could significantly impact drug-drug interactions.
Methods
The researchers utilized the Caco-2 cell line, a human colorectal adenocarcinoma model that mimics the human small intestine when grown in a monolayer.
- Transport Assays: Movement was measured from the apical (gut) side to the basolateral (blood) side and vice versa.
- Inhibitor Challenges: Known inhibitors (verapamil for P-gp and glibenclamide for MRP2) were used to determine if tryptanthrin's transport was mediated by these proteins.
- Substrate Inhibition: The study tested if tryptanthrin could block the efflux of established substrates, specifically digoxin (P-gp) and pravastatin sodium (MRP2).
- Genetic Analysis: RT-PCR was employed to determine if tryptanthrin altered the mRNA expression levels of the MDR1 and MRP2 genes.
Results
High Permeability via Passive Diffusion
Tryptanthrin demonstrated high intestinal permeability, with an apparent permeability coefficient ($P_{app}$) of $6.138 \times 10^{-5}$ cm/s in the absorptive direction. Values above $1 \times 10^{-5}$ are generally considered indicative of a well-absorbed compound. The efflux ratio was 0.77, suggesting that the molecule naturally favors absorption into the body. Because transport was concentration-independent, the researchers concluded that passive diffusion is the primary mechanism of entry.
Functional Inhibition of Efflux Pumps
Crucially, while tryptanthrin transport was not affected by P-gp or MRP2 inhibitors (confirming it is not a substrate), it acted as a potent inhibitor of these transporters. In the presence of tryptanthrin, the secretory transport of the P-gp substrate digoxin was significantly reduced (Figure 5). Similar results were observed for the MRP2 substrate pravastatin sodium, with efflux decreasing by more than 30%.
Direct Protein Interaction
RT-PCR results confirmed that mRNA levels for MDR1 and MRP2 remained stable during the 4-hour experimental window. This suggests that the inhibition is a result of direct interaction with the transporter proteins rather than a change in gene expression.
Discussion and Conclusion
Tryptanthrin is highly permeable and effectively absorbed through the intestinal barrier via passive diffusion. While it is not hindered by major cellular efflux pumps, its role as a functional inhibitor of P-gp and MRP2 is clinically significant. This inhibitory effect could increase the bioavailability of co-administered drugs that are substrates for these pumps, potentially leading to toxic spikes in drug levels. Future clinical studies must carefully evaluate these potential drug-drug interactions to ensure patient safety during tryptanthrin therapy.
Summary updated